Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety and efficacy study of PRX-102 in Fabry disease patients previously treated with Replagal
2016-001318-11Phase 3Completed
- Sponsor
- Protalix BioTherapeutics
- Start
- Oct 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Protalix BioTherapeutics. Primary endpoint: Safety endpoints. Started Oct 2016; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2016-001318-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001318-11.